Corporate News

Indorama increases capacity with strategic investment

Mr. D K Agarwal, CEO of Combined PET, IOD and Fibers Business at Indorama Ventures,

Indo Rama Synthetics (India) Limited (IRSL), a subsidiary of global petrochemical producer Indorama Ventures Public Company Limited (IVL), will spend up to INR 6 billion (USD 82M) upgrading equipment and adding capacity at its manufacturing site in Nagpur, India. The capital expenditure plan includes a new PET resin manufacturing facility, additional balancing equipment, and a large range of specialty yarns, further strengthening IRSL’s ability to serve clients across the country.

India is a strategic market for IVL, where the company operates all three of its global integrated business segments – Combine PET, Fibers, and Integrated Oxides and Derivatives (IOD). IVL has continually developed its PET resin business in India since 2016 through IVL Dhunseri Petrochem Industries Private Limited (IDPIPL), a joint venture with Dhunseri Ventures Limited.

The new PET resin facility at Nagpur will add 700 tons of capacity per day and is expected to be operational by the second quarter of 2022. Together with plants at Haldia and Karnal, the Nagpur facility further strengthens IVL’s position as India’s largest resin producer, with a total capacity of over 1 million tons annually. With three manufacturing locations across the country, IVL serves customers throughout India.

The plant at Nagpur, which IVL has managed since 2019, is also the company’s first fiber manufacturing site in India, offering a wide range of staple fibers and filament yarns. Under the investment plan, it will meet global brands’ increasing demand for more high-quality and sustainable textile products.

Mr. D K Agarwal, CEO of Combined PET, IOD and Fibers Business at Indorama Ventures, said, “India is a strategic high-growth market for us. Our capital expenditure plan reflects our long-term commitment to the industry’s development in India. It is important that we continually invest to ensure that we can serve our customers across India, wherever we are needed.”

24 Replies to “Indorama increases capacity with strategic investment

  1. Amiodarone Cordarone Arsenic Trioxide Trisenox Bleomycin Blenoxane Bortezomib VelcadeTM Busulfan Busulfex Calcium salts Conivaptan Vaprisol Carboplatin Paraplatin Carmustine BiCNU Cisplatin Platinol Cladribine Leustatin Dacarbazine DTIC- Dome Dalfopristin quinupristin Synercid Dextrose Docetaxel Taxotere Erythromycin Esmolol Brevibloc Etoposide VePesid Etoposide phosphate Etopophos Fluorouracil Gemcitabine Gemzar Gentamicin Ifosfamide Ifex Irinotecan Camptosar Liposomal cytarabine DepoCyt Liposomal daunorubicin DaunoXome Liposomal doxorubicin Doxil Liposomal vincristine Marqibo Melphalan Alkeran Nafcillin Nallpen Paclitaxel Taxol Paclitaxel, nanoparticle albumin- bound Abraxane Plicamycin Mithracin Potassium chloride Sodium chloride 1 or 170 mEq L Streptozocin Streptozotocin, Zanosar Teniposide Vumon Thiotepa Topotecan HycamtinTM Vancomycin. should doxycycline be taken with food He just started an antibiotic yesterday, Doxycycline; 100mg twice daily.

  2. Paraffin embedded tissue sections from 619 archived invasive BCs were selected from the Histopathology Department of Temuco Hospital Chile, Hospital General de Agudos Juan A lasix generic

  3. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions ethacrynic acid to lasix conversion The new use of the drug is unexpected, as tamoxifen s only previously known association with the retina had been a low risk of retinopathy among breast cancer patients

Leave a Reply

Your email address will not be published.